Challenges In AML Treatment
Elderly patients with AML have long faced limited options for their treatment, but that is no longer the case. However, challenges still remain in the treatment of this patient population.
Related Articles
Complex Multidisciplinary Care of an AYA With Ewing Sarcoma
This case demonstrates the pivotal role of a cohesive multidisciplinary team in navigating the complex care of oncology patients from diagnosis, treatment, and posttreatment surveillance.
Rate of Cardiovascular Adverse Events, Myocarditis May Be Low in Trials Assessing ICIs
Even with a low rates of cardiovascular adverse events in patients treated with immune checkpoint inhibitors, cancer care teams should still focus on multidisciplinary approaches…
The Changing Landscape of Clinical Trials in Cancer Care
Although excitement surrounds the constantly changing landscape of cancer care, we have much to learn to keep our practices current.
BCMA/CD19–Targeting CAR T-Cell Therapy Safely Produces Favorable Outcomes in Newly Diagnosed Multiple Myeloma
GC012F, a BCMA/CD19–targeted CAR T-cell therapy, safely produced favorable outcomes in patients with newly diagnosed multiple myeloma after induction therapy.
Two Phase 3 Trials of Pembrolizumab in NSCLC, CSCC to Be Discontinued By Merck
Merck has discontinued the KEYNOTE-867 and KEYNOTE-630 trials evaluating pembrolizumab in non-small cell lung cancer and cutaneous squamous cell carcinoma.
Companion Diagnostics for Olaparib Plus Abiraterone Acetate Gains FDA Approval in BRCA+ mCRPC
Companion diagnostics have been approved by the FDA for olaparib plus abiraterone in patients with metastatic castration-resistant prostate cancer.
Longer Duration of Adjuvant Trastuzumab May Further Improve DFS Rates in ERBB2-Positive Breast Cancer
Adjuvant trastuzumab reveals associations with improved disease-free survival in 1-year vs 9-week administration of the drug in patients with ERBB2-positive breast cancer.
Bortezomib Injectable Receives FDA Approval for Multiple Myeloma and MCL
The FDA approved Boruzu, a new presentation of bortezomib, for subcutaneous or intravenous administration in patients with multiple myeloma and mantle cell lymphoma.
Active Surveillance May Benefit Certain Patients With Small Nonfunctional Pancreatic NETs
This retrospective review demonstrates the increased use of active surveillance in patients with small nonfunctional pancreatic neuroendocrine tumors.
Tisagenlecleucel Moves to Earlier Lines of Therapy for Pediatric, Young Adults With Relapsed/Refractory B-ALL
Pediatric and young adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia are receiving tisagenlecleucel in earlier lines of therapy.